ALNY - アルナイラム・ファ―マシュ―ティカルズ (Alnylam Pharmaceuticals Inc.) アルナイラム・ファ―マシュ―ティカルズ

 ALNYのチャート


 ALNYの企業情報

symbol ALNY
会社名 Alnylam Pharmaceuticals Inc (アルナイラム・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アルナイラム・ファーマシューティカルズ(Alnylam Pharmaceuticals Inc.)はリボ核酸干渉法(RNAi)に基づく治療薬を開発する生物医薬品会社である。同社の「Alnylam 5x15」は遺伝的疾患の治療向けに、リボ核酸干渉法を用いた新規治療薬の開発及び商品化に注力する。同社の臨床または前臨床開発段階の中核プログラムには、トランスサイレチン媒介性アミロイドーシス(ATTR)の治療向けの「ALN-TTR」、血友病の治療向けの「ALN-APC」、重度の高コレステロール血症の治療向けの「ALN-PCS」、不応性貧血の治療向けの「ALN-HPN」、並びにベータサラセミア及び鎌状赤血球貧血症を含む異常ヘモグロビン症の治療向けの「ALN-TMP」が含まれる。パートナーベースのプログラムとしては、同社は呼吸器合胞体ウイルス(RSV)感染症の治療向けの「ALN-RSV01」、肝癌の治療向けの「ALN-VSP」、並びにハンチントン病(HD)の治療向けの「ALN-HTT」を含む臨床または前臨床開発段階のプログラムを3つ有する。   アルナイラム・ファ―マシュ―ティカルズは米国のバイオテクノロジ―企業。2002年の創業以来、一貫してRNAi(各種疾患の原因となるタンパク質を作り出す遺伝子に直接・選択的に作用する特徴を有する)技術を基盤とした医薬品研究開発を行い、RNAi医薬の研究・開発に必要な多くの特許、技術を保持する。本社はマサチュ―セッツ州ケンブリッジ。   
本社所在地 300 Third Street Cambridge MA 02142 USA
代表者氏名 Michael W. Bonney マイケル・W・ボニー
代表者役職名 Independent Chairman of the Board
電話番号 +1 617-551-8200
設立年月日 37742
市場名 NASDAQ National Market System
ipoyear 2004年
従業員数 749人
url www.alnylam.com
nasdaq_url https://www.nasdaq.com/symbol/alny
adr_tso
EBITDA EBITDA(百万ドル) -600.14400
終値(lastsale) 83.21
時価総額(marketcap) 8376427179.52
時価総額 時価総額(百万ドル) 8222.408
売上高 売上高(百万ドル) 106.82600
企業価値(EV) 企業価値(EV)(百万ドル) 6804.742
当期純利益 当期純利益(百万ドル) -570.73800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Alnylam Pharmaceuticals Inc. revenues increased 48% to $51.8M. Net loss before extraordinary items increased 35% to $305.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative - Balancing v increase from $40.5M to $87.2M (expense).

 ALNYのテクニカル分析


 ALNYのニュース

   Alnylam's Oxalate-Lowering Therapy Shows Significant Clinical Benefit; Data Published In New England Journal Of Medicine  2021/04/01 12:55:27 Benzinga
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY ) has announced that trial results from the ILLUMINATE-A Phase 3 study evaluating lumasiran for the treatment of primary hyperoxaluria type 1 (PH1). The results were published online in The New England Journal of Medicine. Lumasiran an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) In November last year, Oxlumo (lumasiran) was approved by the FDA to treat PH1 … Full story available on Benzinga.com
   Global Oligonucleotide Therapy Market Report 2020-2030: COVID-19 Impacts, Growth and Changes - ResearchAndMarkets.com  2021/03/23 14:36:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Oligonucleotide Therapy Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. The global oligonucleotide therapy market is expected to decline from $0.9 billion in 2019 to $0.88 billion in 2020 at a compound annual growth rate (CAGR) of -2.1%. Major players in the oligonucleotide therapy market are Alnylam Pharmaceuticals Inc., Biogen Inc., Dynavax Technologies Corp., Ionis Pharmaceuticals Inc., Merck
   Alnylam to Present Full 9-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the American Academy of Neurology Virtual Annual Meeting 2021  2021/03/23 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present full 9-month results from the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of the polyneuropathy of hereditary ATTR (hATTR) amyloidosis, at the American Academy of Neurology (AAN) Virtual Annual Meeting, being held April 17-22. The Company previously announced positive t
   Transthyretin Amyloidosis Treatment Market - Alnylam Pharmaceuticals, Inc., Pfizer, Inc., Prothena Corporation Plc., GlaxoSmithKline Plc., Ionis Pharmaceuticals, Inc., Eidos Therapeutics, and SOM Innovation Biotech, S.L.  2021/03/08 06:30:34 OpenPR
Transthyretin Amyloidosis Treatment Market Report 2020-2027 includes a comprehensive analysis of the present Market. The report starts with the basic Transthyretin Amyloidosis Treatment industry overview and then goes into each and every detail. Transthyretin Amyloidosis Treatment Market Report contains in depth
   RNAi Therapeutics Market Insight & Future Assessment for the Period – 2027 Analysis Focusing on Update Top Key Players - Alnylam Pharmaceuticals, Inc., Sanofi, Olix Pharmaceuticals, Inc., Glaxosmithkline Plc., Benitec Biopharma, Arbutus Biopharma Corpor  2021/03/05 14:39:40 OpenPR
The RNAi therapeutics market was valued at US$ 618.79 million in 2019 and is projected to reach US$ 1,209.29 million by 2027; it is expected to grow at a CAGR of 8.8% from 2020 to 2027. The report highlights
   Alnylam's Oxalate-Lowering Therapy Shows Significant Clinical Benefit; Data Published In New England Journal Of Medicine  2021/04/01 12:55:27 Benzinga
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY ) has announced that trial results from the ILLUMINATE-A Phase 3 study evaluating lumasiran for the treatment of primary hyperoxaluria type 1 (PH1). The results were published online in The New England Journal of Medicine. Lumasiran an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) In November last year, Oxlumo (lumasiran) was approved by the FDA to treat PH1 … Full story available on Benzinga.com
   Global Oligonucleotide Therapy Market Report 2020-2030: COVID-19 Impacts, Growth and Changes - ResearchAndMarkets.com  2021/03/23 14:36:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Oligonucleotide Therapy Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. The global oligonucleotide therapy market is expected to decline from $0.9 billion in 2019 to $0.88 billion in 2020 at a compound annual growth rate (CAGR) of -2.1%. Major players in the oligonucleotide therapy market are Alnylam Pharmaceuticals Inc., Biogen Inc., Dynavax Technologies Corp., Ionis Pharmaceuticals Inc., Merck
   Alnylam to Present Full 9-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the American Academy of Neurology Virtual Annual Meeting 2021  2021/03/23 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present full 9-month results from the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of the polyneuropathy of hereditary ATTR (hATTR) amyloidosis, at the American Academy of Neurology (AAN) Virtual Annual Meeting, being held April 17-22. The Company previously announced positive t
   Transthyretin Amyloidosis Treatment Market - Alnylam Pharmaceuticals, Inc., Pfizer, Inc., Prothena Corporation Plc., GlaxoSmithKline Plc., Ionis Pharmaceuticals, Inc., Eidos Therapeutics, and SOM Innovation Biotech, S.L.  2021/03/08 06:30:34 OpenPR
Transthyretin Amyloidosis Treatment Market Report 2020-2027 includes a comprehensive analysis of the present Market. The report starts with the basic Transthyretin Amyloidosis Treatment industry overview and then goes into each and every detail. Transthyretin Amyloidosis Treatment Market Report contains in depth
   RNAi Therapeutics Market Insight & Future Assessment for the Period – 2027 Analysis Focusing on Update Top Key Players - Alnylam Pharmaceuticals, Inc., Sanofi, Olix Pharmaceuticals, Inc., Glaxosmithkline Plc., Benitec Biopharma, Arbutus Biopharma Corpor  2021/03/05 14:39:40 OpenPR
The RNAi therapeutics market was valued at US$ 618.79 million in 2019 and is projected to reach US$ 1,209.29 million by 2027; it is expected to grow at a CAGR of 8.8% from 2020 to 2027. The report highlights
   Chardan Capital Stick to Their Buy Rating for Alnylam Pharmaceuticals By Investing.com  2021/02/12 13:35:48 Investing.com
Chardan Capital Stick to Their Buy Rating for Alnylam Pharmaceuticals
   Oppenheimer Stick to Their Hold Rating for Alnylam Pharmaceuticals By Investing.com  2021/02/12 09:55:00 Investing.com
Oppenheimer Stick to Their Hold Rating for Alnylam Pharmaceuticals
   Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity  2021/02/11 13:00:00 Business Wire
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth
   Earnings Scheduled For February 11, 2021  2021/02/11 08:51:42 Benzinga
Companies Reporting Before The Bell • Bluerock Residential Growth REIT, Inc. Class A Common Stock (AMEX: BRG ) is expected to report quarterly loss at $0.55 per share on revenue of $54.86 million. • AllianceBernstein Holding (NYSE: AB ) is expected to report quarterly earnings at $0.81 per share on revenue of $805.56 million. • Applied Genetic (NASDAQ: AGTC ) is likely to report earnings for its second quarter. • Alnylam Pharmaceuticals (NASDAQ: ALNY ) is projected to report quarterly loss at $1.76 per share on revenue of $146.07 million. • Alithya Group (NASDAQ: ALYA ) is expected to report earnings for its third quarter. • AstraZeneca (NASDAQ: AZN ) is likely to report quarterly earnings at $0.68 per share on revenue of $6.97 billion. • Coca-Cola European (NYSE: CCEP ) is expected to report earnings for its fourth quarter. • Cohu (NASDAQ: COHU ) is expected to report quarterly earnings at $0.61 per share on revenue of $197.76 million. • CSP (NASDAQ: CSPI ) is estimated to report earnings for its first quarter.
   Global RNA Therapeutics Market Growth Factors,Opportunities,Trends Outlook 2021||Quark, Alnylam Pharmaceuticals, Inc Dicerna Pharmaceuticals, Tekmira Pharmaceuticals, Benitec Biopharma  2021/02/09 15:05:28 OpenPR
A persuasive RNA Therapeutics report is an ideal guide to attain an information or key data about market, emerging trends, product usage, and motivating factors for customers, customer preferences, competitor strategies, brand positioning, and customer behavior. The report provides wide-ranging

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アルナイラム・ファ―マシュ―ティカルズ ALNY Alnylam Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)